

A Divergent Enantioselective Synthesis of 9-J₁-Phytoprostane and 9-A₁-Phytoprostane Methyl Ester

Alessio Porta,*^[a] Francesco Chiesa,^[a] Marco Quaroni,^[a] Marco Persico,^[b] Remigio Moratti,^[b] Giuseppe Zanoni,^[a] and Giovanni Vidari^[a]

Keywords: Total synthesis / Asymmetric synthesis / Olefination / Natural products / Phytoprostanes

The first syntheses of 9-J₁-phytoprostane and 9-A₁-phytoprostane methyl ester were achieved enantioselectively using a divergent approach from a common intermediate sulfone 4. The divergence was accomplished using a sigmatropic rearrangement (swap protocol) to give sulfone 5 in 47 % overall

yield. The two upper side-chains, with a stereodefined Edouble bond, were installed using consolidated Julia–Lythgoe olefination reactions of sulfones 4 and 5, with the same enantiopure α -protected aldehyde **6**.

Introduction

Phytoprostanes (PhytoPs) are prostaglandin-like compounds produced in plants by nonenzymatic free-radical peroxidation of membrane-bound α -linolenic acid.^[1] The main differences between most PhytoPs chiefly and the prostaglandins are in the lengths and the thermodynamically less stable *cis* stereochemical relationship of the two side-chains on the five-membered ring. Another important feature of the nonenzymatic pathway to natural phytoprostanes is the absence of control of the absolute stereochemistry of the stereogenic centres of the cyclopentane ring and the allylic hydroxy group. There are seven classes of phytoprostanes, which, in analogy to the prostaglandin nomenclature system, have been named PPA₁, PPB₁, PPD₁, PPE₁, PPF₁, PPJ₁, and PPL₁, with the latter being the regioisomer of PPB₁.^[2a] (Figure 1).

It should be pointed out that the compounds of each of the classes of phytoprostanes have two possible regioisomers, i.e., the 9 and 16 regioisomers, each of which com-



Figure 1. Representative phytoprostanes of the A₁, B₁, D₁, E₁, F₁, J₁, and L₁ classes.

- Viale Golgi 19, 27100 Pavia, Italy
- Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201301703.

prises several stereoisomers due to the stereocentres of the prostanoid ring. Accordingly to the more recent proposed phytoprostane nomenclature system, our synthetic targets were 9-J₁-PhytoP (1) and 9-A₁-PhytoP (2),^[2a,2b] which correspond to PPA₁-II and PPJ₁-II, respectively, in an older nomenclature system.^[2c] Phytoprostane 9-J₁-PhytoP (1) has been detected in tobacco cell cultures after an induced oxi-

[[]a] Department of Chemistry, University of Pavia, Viale Taramelli 10, 27100 Pavia, Italy E-mail: aporta@unipv.it http://b2chem.unipv.it [b] Foundation IRCCS San Matteo,

FULL PAPER

dative stress, and also, in very low quantities, in tomato plants infected with the necrotrophic fungus Botrytis ci*nerea*.^[3] The isolation and characterization of 9-J₁-PhytoP, has also been claimed, but in fact, the reported spectroscopic data correspond to the respective dehydration product. On the other hand, $9-A_1$ -PhytoP (2) is too elusive to have been isolated and characterized.^[2a,4] A few biological activities have been attributed to cyclopentenone 9-J₁-phytoprostane (1) both in plants and in humans. For example, In plants, 9-J₁-PhytoP significantly activated the mitogenactivated protein kinase in cell suspension of tomato cultures, and induced a high expression of the orthologous gene in tobacco. Moreover, 1 induced glutathione-S-transferase 1 expression in Arabidopsis; this enzyme plays a key role in the detoxification of reactive electrophiles, thus triggering an adaptive response in plants and partially preventing cell death.^[5] In humans, J₁-phytoprostanes show significant anti-inflammatory activity in HEK 293 cells and RAW 264.7 macrophages, through the down-regulation of the NF- κ B signalling pathway and the inhibition of nitric oxide synthesis, respectively. In addition, 9-J₁-PhytoP shows antitumor activity by inducing the apoptosis of leukaemia Jukart T cells.^[6] Considering that J₁-phytoprostanes have been detected in edible oils,^[6] it is of paramount importance to clarify their physiological activity, as has been done for prostanoids and isoprostanes in animals.^[1c] This is especially true for the elusive 9-A1-phytoprostane, whose biological activity is unknown. A detailed evaluation of the biological activities of 9-J₁-PhytoP and 9-A₁-PhytoP has been prevented so far by the poor availability of the pure compounds.

Thus, the chemical synthesis of 9-J₁-PhytoP and 9-A₁-PhytoP is not only a highly challenging goal, but it is the only way to prepare enough material for biological studies.

However, no synthesis of 9-J₁-PhytoP or 9-A₁-PhytoP has been reported in the literature to date.

Results and Discussion

In this paper, we describe the first enantioselective divergent synthesis of cyclopentenone phytoprostane 1 and the methyl ester of 2, starting from a common chiral building block, namely the enantiopure hydroxymethyl γ -lactone (–)-(3a*S*,4*S*,6a*R*)-3, which is available on a multigram scale.^[7] According to our retrosynthetic strategy (Scheme 1), the upper side-chains (α side-chains) of phytoprostanes 1 and 2, with a stereodefined *E* double bond, were installed by consolidated Julia–Lythgoe olefination reactions of sulfones 4 and 5, respectively, with enantiopure α -protected aldehyde 6.

The *S* absolute stereochemistry of the alcohol in the α side-chain precursor **6** was secured by a regio- and stereocontrolled nucleophilic oxirane ring-opening of (*S*)-glycidyl benzyl ether **8** by hept-6-ynoic acid TIPS ester **7**. Sulfone **5** converged to sulfone **4** via cyclopentenyl aryl selenoether intermediate **9** using our swap protocol.^[8] The ethyl group of the ω side-chain of **1** and the methyl ester of **2** was obtained from the reduction of tosylhydrazone **10** with (Ph₃P)₂CuBH₄ to give the corresponding hydrocarbon.^[9] Retrosynthetically, simple functional group manipulations indicated that lactone **3** was the ideal precursor.

The enantioselective synthesis of phytoprostanes 1 and the methyl ester of 2 thus began with the preparation of enantiopure *O*-TBS-protected α -hydroxyaldehyde 6 (Scheme 2). In the event, nucleophilic addition of the alkynide anion of hept-6-ynoic acid TIPS ester 7 to commercially available enantiopure (*S*)-glycidyl benzyl ether 8 under



Scheme 1. Retrosynthesis of $9-J_1$ - and $9-A_1$ -phytoprostanes; Ts = 4-tolylsulfonyl, EE = ethoxyethyl, TBDPS = *tert*-butyldiphenylsilyl, TIPS = triisopropylsilyl, Ar = 2-nitrophenyl.



Scheme 2. Synthesis of α side-chain precursor **6**. Reagents and conditions: a) **7**, BuLi, -78 °C, 1 h, then BF₃·Et₂O, 10 min. then **8**, -78 °C, 2 h; b) i. K₂CO₃, THF/H₂O (1:1), room temp., 4 d; ii. CAL-B lipase, MTBE/MeOH (9:1), room temp., 30 h, 70%; c) TBSCl, imidazole, CH₂Cl₂, room temp., 36 h, quant.; d) Pd/C (10%), H₂, EtOAc/MeOH (9:1), room temp., 7 d, 86%; e) DMP, CH₂Cl₂, room temp., 1 h, 75%. DMP = Dess-Martin periodinane, MTBE = methyl *tert*-butyl ether, CAL-B = *Candida antarctica* lipase B, TBSCl = *tert*-butyl imethylsilyl chloride.

Yamaguchi conditions^[10] (BuLi, -78 °C, followed by BF₃·Et₂O, and then epoxide **8**) gave alcohol **11** as a single regioisomer, which was used in the next step without purification.

Transesterification of TIPS ester 11, in the presence of the free C-9 hydroxy group, was accomplished in a biocatalytic approach using *Candida antarctica* lipase B (CAL-B) in the presence of MeOH at room temp. The corresponding methyl ester (i.e., 12) was thus obtained in a satisfactory 70% isolated yield over three steps. Subsequently, alcohol 12 was protected as its TBS ether 13, and then the triple bond was fully reduced [Pd on carbon (10%), H₂ (1 atm), EtOAc/MeOH, 9:1] with concomitant benzyl ether cleavage, to give saturated primary alcohol 14 in 86% overall yield. Dess–Martin periodinane oxidation^[11] of alcohol 14 smoothly delivered aldehyde 6, $[a]_{D}^{20} = -22.1$ (c = 1.55, CH₂Cl₂), in 75% isolated yield.

Having established an efficient route to key intermediate **6**, we then turned our attention to the enantioselective synthesis of the two phytoprostane cores **4** and **5**, and this was achieved by the reaction sequences shown in Scheme 3.

Enantiopure hydroxymethyl lactone $3^{[7]}$ was converted into sulfide **15** in 88% yield with PhSSPh in the presence of *n*Bu₃P and pyridine at room temp. Tosylhydrazone **10** was then obtained in three steps in 63% overall yield. DI-BAL-H reduction of **15** at -78 °C gave the corresponding lactol, which was then treated with tosylhydrazine in dry THF at room temp., followed by protection of the allylic alcohol with TBDPSCl in the presence of imidazole in CH₂Cl₂ at room temp. After some experiments, the crucial reduction of **10** to give ethyl derivative **16** was achieved with (Ph₃P)₂CuBH₄ in refluxing dry CHCl₃ for 3 h;^[9] compound **16** was thus obtained in 55% isolated yield, $[a]_{D}^{20} = 39.1$ (*c* = 0.35, CH₂Cl₂). Subsequently, sulfone **4**, a key building



Scheme 3. Synthesis of key sulfones 4 and 5. Reagents and conditions: a) PhSSPh, THF, 0 °C to room temp. 88%; b) i. DIBAL-H, CH₂Cl₂, -78 °C, 1 h, 95%; ii. TsNHNH₂, THF, room temp., 18 h, 99%; iii. TBDPSCl, CH₂Cl₂, imidazole, room temp., 2 d, 70%; c) (Ph₃P)₂CuBH₄, CHCl₃, 70 °C, 3 h, 55%; d) H₂O₂ (50% v/v solution), (NH₄)MoO₄ (cat.), room temp., 2 d, 50%; e) i. TBAF (1 M in THF), THF, room temp., 2 d, 70%; ii. 2-nitrophenyl selenocyanate, *n*Bu₃P, THF, room temp., 1 h, 90%; f) i. H₂O₂ (35% v/v solution), pyridine, 0 °C to 4 °C, 18 h, 60%; ii. Ethyl vinyl ether, CH₂Cl₂, PPTS, room temp., 4 h, 87%; PPTS = pyridinium *p*-toluenesulfonate, Ts = *p*-tolylsulfonyl, TBDPSCl = *tert*-butyldiphenylsilyl chloride, TBAF = tetrabutylammonium fluoride, DIBAL-H = diisobutylaluminium hydride.



Scheme 4. Finale of the total synthesis of phytoprostanes 1 and 21. Reagents and conditions: a) i. TBAF (1 μ in THF), THF, room temp., 5 d, 70%; ii. Ethyl vinyl ether, CH₂Cl₂, PPTS, room temp., 4 h, 80%; b) i. 17, BuLi (2.5 μ in hexane), THF, -78 °C, 40 min, then 6 in THF, -78 °C, 4 h; ii. Na₂HPO₄, MeOH, -40 °C, then Na (20% Hg), -40 °C to -20 °C, 2 h, 61%; c) i. PPTS, EtOH/CH₂Cl₂ (3:1), room temp., 4 h, 91%; ii. DMP, CH₂Cl₂, room temp., 1.5 h, 95%; d) i. HF (48% aq. v/v), MeCN, room temp., 4 h, 93%; ii. CAL-B, H₂O, MTBE, room temp., 1 d, 90%; e) NH₄F, MeOH, room temp., 4 h, 65%.

block for the synthesis of phytoprostane **1** and the divergent synthesis of phytoprostane **2** was easily prepared by chemoselective oxidation of **16** with H_2O_2 in the presence of a catalytic amount of $(NH_4)_2MoO_4$ in methanol at room temp.^[12] A divergent route to **2** from sulfone **4** was accomplished after cleavage of the TBDPS group, using our "swap" strategy,^[8] via 2-nitrophenyl selenyl ether **9**, which was prepared in 90% yield using 2-nitrophenyl selenocyanate in the presence of *n*Bu₃P in THF at room temp. Hydrogen peroxide [H₂O₂ (30%), pyridine, THF, 7 °C] smoothly triggered the [2,3]-sigmatropic rearrangement of the corresponding secondary allylic selenoxide **9a** to give the desired alcohol (i.e., **5a**) in 60% isolated yield. This alcohol was subsequently protected as its ethoxyethyl ether **5** (ethyl vinyl ether, CH₂Cl₂, pyridinium *p*-toluenesulfonate, 87% yield).

With the two key sulfones 4 and 5 in hand, the synthesis was expected to proceed readily to give target phytoprostanes 1 and 21, respectively (Scheme 4), using the same olefination strategy for both compounds to introduce the unsaturated side-chains. In the event, simple functional group manipulation in 4 gave EE-protected sulfone 17, which was condensed with aldehyde 6 under our modified Julia-Lythgoe olefination conditions^[13] to give olefin **18** as a single E stereoisomer (13 C NMR spectroscopy) in 61% isolated yield over two steps. Removal of the labile EE protecting group [abs. EtOH/CH₂Cl₂ (3:1), pyridinium p-toluenesulfonate, room temp., 91% yield], followed by Dess-Martin periodinane oxidation, gave the corresponding enone (i.e., 19) in 95% isolated yield. Finally, two consecutive deprotection steps, namely O-TBS ether cleavage with aq. HF, and methyl ester hydrolysis under our "buffer-free" conditions,^[14] delivered the expected 9-J₁-PhytoP (1), $[a]_D^{20}$ = -170.4 (c = 0.55, CH₂Cl₂), in 84% yield over two steps. Following the same synthetic sequence used for the transformation of 4 into enone 19, sulfone 5 gave the expected enone (i.e., 20; see Supporting Information), from which the *O*-TBS ether was detached using NH₄F in MeOH instead of aq. HF, in order to prevent a biomimetic dehydration^[2a,4] (Scheme 4) of the corresponding free alcohol. Under these conditions, the elusive 9-A₁-PhytoP (2) was obtained as its methyl ester (i.e., 21) in 65% isolated yield, $[a]_D^{20} = 67.5$ (c = 0.12, CH₂Cl₂). The extreme instability of the 9-A₁-phytoprostane structure is reflected in both the yield of the crucial Dess–Martin oxidation (31%) en route to 20, and the extensive decomposition of 9-A₁-PhytoP methyl ester 21 that was observed during an attempted hydrolysis under extremely mild CAL-B mediated conditions.^[15]

Conclusions

In summary, the first enantioselective divergent synthesis of the elusive cyclopentenone 9-J₁-phytoprostane 1 and of 9-A₁-phytoprostane methyl ester 21 has been accomplished starting from the common chiral building block 3, which is available in multigram amounts in enantiopure form. Further studies aiming for the total synthesis of the other two regioisomeric A₁ and J₁ cyclopentenone phytoprostanes, 16-J₁-PhytoP and 16-A₁-PhytoP, are in progress in our laboratory, and the results will be reported in due course.

Experimental Section

General Information: THF was distilled from sodium with benzophenone ketyl radical as indicator. CHCl₃ and CH₂Cl₂ were distilled from CaH₂. All moisture-sensitive reactions were carried out under O₂-free Ar using oven-dried glassware and a vacuum line. Flash column chromatography was carried out using Merck SiO₂ 60 (230–400 mesh), and TLC was carried out using commercially available Merck F254 precoated sheets. Visualization of reaction components was achieved under UV light at a wavelength of 254 nm, or by staining by exposure to vanillin (0.5% solution in H₂SO₄/EtOH) followed by gentle heating. ¹H and ¹³C NMR spectra were recorded with a Bruker Avance 300 instrument. Chemical

shifts are given in ppm, and are referenced using the residual signals of the solvent as internal standard (¹H: CHCl₃, δ = 7.26 ppm; [D₅]acetone, δ = 2.05 ppm. ¹³C: CDCl₃, δ = 77.0 ppm). IR spectra were recorded with a Perkin–Elmer Paragon 100 PC spectrometer. Mass spectra were recorded with a Thermo LTQ-XL mass spectrometer (H-ESI) or a Finnigan MAT-90 mass spectrometer. Melting points were determined using an OptiMelt MPA100 device from Stanford Research Systems.

(*E*)-*N*'-(2-{(1*R*,2*S*,5*R*)-2-[(*tert*-Butyldiphenylsilyl)oxy]-5-[(phenylthio)methyl]cyclopent-3-en-1-yl}ethylidene)-4-methylbenzenesulfonohydrazide (10): A stirred solution of sulfide 15 (260 mg, 1.057 mmol) in CH₂Cl₂ (10 mL) was cooled to -78 °C, and DIBAL-H (1 m in hexane; 1.3 mL, 1.2 equiv.) was added dropwise. Stirring was continued for an additional 1 h, and then a saturated solution of NH₄Cl (10 mL) was added at -78 °C. The mixture was gradually warmed to room temp., then it was diluted with CH₂Cl₂ (30 mL), and acidified with concentrated HCl. The aqueous layer was extracted with CH₂Cl₂ (3 × 25 mL), and the combined organic phases were washed with H₂O and brine, and dried with MgSO₄. The volatiles were evaporated in vacuo to give the desired lactol (256 mg, 98%), a 9:1 mixture of diastereomeric hemiacetals, as a white solid, m.p. 107–110 °C. Spectroscopic data are in agreement with the literature.^[13]

TsNHNH₂ (284 mg, 1.3 mmol, 1.2 equiv.) was added portionwise to a stirred solution of the sulfide lactol (276 mg, 1.1 mmol) in dry THF (11 mL) at room temperature. Stirring was continued for 18 h, and then the volatiles were removed under reduced pressure. Imidazole (6 equiv., 332 mg) and TBDPS chloride (2.5 equiv., 0.53 mL) were added to a stirred solution of the crude hydrazone (0.34 g, 0.815 mmol) in dry CH₂Cl₂ (8 mL) under an Ar atmosphere. After 40 h, H₂O (15 mL) was added, and the layers were separated. The aqueous phase was then extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were washed with brine, dried with MgSO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel. Elution with *n*-hexane/Et₂O (7:3) gave silyl ether 10 (361 mg, 70%) as a colourless oil. IR (neat): v = 3204.1, 3061, 2929, 2857, 1587, 1480, 1471, 1428, 1360, 1320, 1186, 1166, 1111, 1055, 885, 814, 739 cm⁻¹. ¹H NMR (300 MHz. CDCl₃): δ = 7.88–7.19 (m, 21 H), 6.90 (s, 1 H), 6.11 (dd, J = 5.8, 2.6 Hz, 1 H), 5.68 (d, J = 5.8 Hz, 1 H), 4.51 (dd, J = 5.6, 2.3 Hz, 1 H), 3.13 (dd, J = 12.2, 5.2 Hz, 1 H), 2.93–2.24 (m, 8 H), 1.03 (d, J = 13.1 Hz, 9 H) ppm. ¹³C NMR $(75 \text{ MHz}, \text{ CDCl}_3): \delta = 151.8 \text{ (d)}, 149.7 \text{ (s)}, 144.1 \text{ (s)}, 138.5 \text{ (d)},$ 137.7 (s), 136.8 (s), 136.0 (d), 135.9 (d), 135.8 (d), 135.2 (s), 134.0 (s), 133.8 (s), 133.6 (d), 133.3 (s), 130.0 (s), 129.8 (d), 129.7 (s), 129.6 (d), 129.5 (s), 129.0 (d), 128.9 (d), 128.8 (d), 128.0 (d), 127.8 (d), 127.5 (d), 126.2 (d), 125.8 (d), 77.1 (d), 45.2 (d), 45.0 (d), 44.4 (d), 43.8 (d), 36.4 (t), 36.2 (t), 28.5 (t), 27.0 (q), 23.4 (t), 21.6 (q), 19.2 (s), 19.1 (s) ppm. MS (ESI): m/z (%) = 662 (100) [M + Na]⁺, 639 (20). HRMS: calcd. for C₃₈H₄₂N₂O₃S₂ 638.2637; found 638.2629.

tert-Butyl({(1*S*,4*R*,5*R*)-5-ethyl-4-[(phenylthio)methyl]cyclopent-2en-1-yl}oxy)diphenylsilane (16): (PPh₃)₂CuBH₄ (285 mg, 0.474 mmol, 1.1 equiv.) was added to a stirred solution of hydrazone 10 (282 mg, 0.43 mmol) in dry CHCl₃ (4 mL). The reaction mixture was heated at reflux for 3 h, and then it was filtered through short Celite pad. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel. Elution with *n*-hexane/Et₂O (97:3) gave 16 (112 mg, 55%) as a colourless oil. $[a]_{D}^{20} = +39.1$ (c = 3.5, CH₂Cl₂). IR (neat): $\tilde{v} = 3071$, 2932, 2862, 1450, 1422, 1301, 1148, 1110, 1060, 1022, 874, 830 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.67$ (m, 4



H), 7.3 (m, 11 H), 6.25 (dd, J = 2.77, 5.8 Hz, 1 H), 5.66 (dd, J = 1.4, 5.7 Hz, 1 H), 4.5 (dd, J = 2.5, 5.3 Hz, 1 H), 3.36 (dd, J = 4.4, 12.2 Hz, 1 H), 3.02 (t, J = 11.4 Hz, 1 H), 2.73 (m, 1 H), 1.78 (m, 4 H), 1.08 (s, 9 H), 0.96 (t J = 7.3 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): $\delta = 139.3$ (d), 137.3 (s), 136.2 (d), 136.1 (d), 135.5 (d), 134.7 (d), 134.2 (d), 133.8 (s), 129.7 (d), 129.4 (d), 128.9 (d), 127.6 (d), 127.4 (d), 125.7 (d), 49.4 (d), 45.4 (d), 37.2 (t), 27.0 (s), 19.3 (d), 18.5 (t), 12.8 (d) ppm. MS (ESI): m/z (%) = 479 (100) [M + Na]⁺. HRMS: calcd. for C₃₁H₃₆OS 456.2487; found 456.2496.

tert-Butyl({(1S,4R,5R)-5-ethyl-4-[(phenylsulfonyl)methyl]cyclopent-2-en-1-yl{oxy)diphenylsilane (4): Sulfide 16 (40 mg, 0.085 mmol) was dissolved in MeOH (8 mL), and the resulting solution was cooled to 0 °C. Solid (NH₄)₂MoO₄ (6 mg) and H₂O₂ (50%; 180 µL, 96 equiv.) were added. The temperature was allowed to reach room temp., and stirring was continued for 3 h. Further H_2O_2 (50%; 70 µL) and (NH₄)₂MoO₄ (4 mg) were added, and the resulting yellow slurry was stirred for an additional 14 h. The reaction was quenched by adding solid Na₂SO₃. The mixture was stirred for 40 min at room temp., then the MeOH was removed by evaporation in vacuo, and the residue was partitioned between a saturated solution of NH₄Cl (6 mL) and CH₂Cl₂ (10 mL). The aqueous phase was extracted with CH_2Cl_2 (3 × 25 mL), and the combined organic layers were washed with brine, and dried with Na₂SO₄. The residue obtained from evaporation of the volatiles was purified on silica gel (8 g; n-hexane/EtOAc, 9:1) to give sulfone 4 (21 mg, 50%) as a pale yellow viscous oil. $[a]_{D}^{20} = +39.5$ (c = 0.4, CH₂Cl₂). IR (neat): $\tilde{v} = 3070, 2931, 2857, 1447, 1428, 1306, 1147, 1112, 1075, 1040,$ 1021, 865, 822 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 7.98 (m, 2 H), 7.62 (m, 7 H), 7.45 (m, 6 H), 6.20 (dd, *J* = 2.83, 5.80 Hz, 1 H), 5.6 (dd, J = 2.02, 5.61 Hz, 1 H), 4.46 (dd, J = 2.52, 5.09 Hz, 1 H), 3.4 (m, 2 H), 2.92 (m, 1 H), 1.9 (m, 1 H), 1.65 (m, 1 H), 1.45 (m, 1 H), 1.12 (s, 9 H), 0.85 (t, J = 7.34 Hz, 3 H) ppm. ¹³C NMR $(75 \text{ MHz}, \text{ CDCl}_3)$: $\delta = 140.0$ (s), 138.1 (d), 136.0 (d), 135.9 (d), 134.6 (d), 134.2 (s), 133.5 (d), 133.4 (s), 129.7 (d), 129.2 (d), 127.8 (d), 127.5 (d), 127.4 (d), 76.3 (d), 59.5 (t), 49.2 (t), 40.0 (d), 26.9 (q), 19.2 (s), 18.5 (t), 12.1 (d) ppm. MS (ESI): m/z (%) = 489 (100) $[M + H]^+$. HRMS: calcd. for $C_{31}H_{36}O_3S$ 488.2385; found 488.2376.

({[(1R,4S,5R)-4-(1-Ethoxyethoxy)-5-ethylcyclopent-2-en-1-yl]methyl}sulfonyl)benzene (17): TBAF (418 µL, 0.12 mmol, 4 equiv.) was added to a solution of 4 (60 mg, 0.1203 mmol) in dry THF (1.2 mL) under Ar. The reaction mixture was stirred at room temp. until complete conversion was reached. The reaction was quenched with saturated aq. NH₄Cl (2 mL), and the mixture was diluted with Et_2O (2 mL). The layers were separated, and the aqueous layer was extracted with Et₂O (3×5 mL). The combined organic layers were washed with brine, dried with Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography on silica gel (n-hexane/EtOAc, 6:4) to give the free alcohol (22.4 mg, 70%). $[a]_D^{20} = -50.0$ (c = 0.5, CH₂Cl₂). IR (neat): $\tilde{v} =$ 3435, 3073, 2933, 2864, 1451, 1426, 1316, 1147, 1045, 1030, 1022, 870 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 7.93 (m, 2 H), 7.6 (m, 3 H), 6.33 (dd, J = 2.12, 5.79 Hz, 1 H), 6.00 (dd, J = 2.66, 5.45 Hz, 1 H), 3.30 (m, 1 H), 3.10 (m, 2 H), 2.04 (m, 1 H), 1.54 (m, 2 H), 1.36 (m, 1 H), 0.97 (m, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 139.9 (s), 139.4 (d), 133.8 (d), 133.7 (d), 129.3 (d), 127.9 (d), 74.8 (d), 59.5 (t), 47.8 (d), 40.0 (d), 18.2 (t), 12.3 (d) ppm. MS (ESI): m/z (%) = 289 (100) [M + Na]⁺. HRMS: calcd. for C₁₄H₁₈O₃S 266.0977; found 266.0983.

The above cyclopentenol (22.4 mg, 0.084 mmol) was dissolved in CH_2Cl_2 /ethyl vinyl ether (7:1; 1 mL), and PPTS (cat.) was added. The resulting mixture was stirred for 4 h, then excess solid NaHCO₃ was added, followed by a saturated solution of NaHCO₃

FULL PAPER

(5 mL). The layers were separated, and the aqueous phase was extracted with CH_2Cl_2 (3 × 15 mL). The combined organic phases were washed with brine, dried with Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel. Elution with n-hexane/ EtOAc (8:2) gave acetal 17 (22.6 mg, 80%, 1:1 mixture of anomers) as a colourless oil. IR (neat): $\tilde{v} = 2972$, 1446, 1306, 1386, 1306, 1147, 1086, 997, 863, 691 cm⁻¹. ¹H NMR (300 MHz, CD₃COCD₃): δ = 7.98 (m, 2 H), 7.71 (m, 3 H), 6.24 (m, 1 H), 6.11 (m, 1 H), 4.72 (m, 1 H), 4.35 (dm 1 H), 3.50 (m, 3 H), 3.01 (m, 2 H), 2.10 (m, 1 H), 1.50 (m, 2 H), 1.18 (m, 6 H), 0.89 (m, 3 H) ppm. ¹³C NMR $(75 \text{ MHz}, \text{CD}_3\text{COCD}_3)$: $\delta = 141.3$ (s), 140.3 (d), 139.3 (d), 134.4 (d), 133.7 (d), 130.2 (d), 128.7 (d), 101.0 (d), 98.7 (d), 81.8 (d), 77.4 (d), 61.2 (t), 60.0 (t), 49.4 (d), 41.5 (d), 21.2 (d), 20.6 (d), 18.9 (t), 15.6 (d), 12.5 (d) ppm. MS (ESI): m/z (%) = 339 (100) [M + H]⁺. HRMS: calcd. for C₁₈H₂₆O₄S 338.1552; found 338.1562.

{(1R,4R,5R)-5-Ethyl-4-[(phenylsulfonyl)methyl]cyclopent-2-en-1yl}(2-nitrophenyl)selane (9): Solid, freshly sublimed (o-nitrophenyl)selenocyanate (136.8 mg, 0.6 mmol, 1.5 equiv.) was added to the cyclopentenol prepared from 4 (see above; 106.6 mg, 0.4 mmol) in dry THF (5 mL) under an argon atmosphere, and then nBu_3P (0.158 mL, 0.64 mmol, 1.6 equiv.) was added dropwise by cannula at room temperature. Stirring was continued for an additional 1 h. The reaction mixture was then diluted with EtOAc, and the organic layer was separated and washed with a saturated solution of NaHCO₃ and then with brine. The combined organic phases were dried with MgSO₄, filtered, and concentrated in vacuo. The oily, brown-orange residue was purified on silica gel. Elution with hexanes/EtOAc (8:2) gave selenide 9 (151 mg, 90%) as a brown-yellow oil. IR (neat): v = 3063, 2964, 2932, 2876, 2255, 1710, 1654, 1590, 1566, 1510, 1448, 1332, 1305, 1148, 1086, 1037, 911, 852, 783, 732, 688 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.3 (dd, J = 1.18, 8.25 Hz, 1 H), 7.9 (m, 2 H), 7.6 (m, 5 H), 7.3 (t, J = 7.14 Hz, 1 H), 6.0 (m, 2 H), 4.2 (m, 1 H), 3.4 (m, 1 H), 3.35 (dd, J = 4.52, 13.84 Hz, 1 H), 3.15 (dd, J = 10.0, 13.81 Hz, 1 H), 2.35 (m, 1 H), 1.5 (m, 2 H), 0.97 (t, J = 7.27 Hz, 3 H) ppm. ¹³C NMR (75 MHz, $CDCl_3$): $\delta = 174.3$ (s), 139.2 (s), 135.4 (d), 133.8 (d), 133.6 (s), 133.3 (d), 131.6 (d), 130.0 (d), 129.4 (d), 128.0 (d), 126.3 (d), 125.7 (d), 56.5 (t), 49.3 (d), 48.8 (d), 40.6 (d), 21.6 (t), 12.3 (q) ppm. MS (ESI): m/z (%) = 452 (100) [M + H]⁺. HRMS: calcd. for $C_{20}H_{21}O_4SSe \ 451.0357; \ found \ 451.0361.$

({[(1S,2S,5S)-2-(1-Ethoxyethoxy)-5-ethylcyclopent-3-en-1yl|methyl}sulfonyl)benzene (5): Pyridine (126 mg, 1.568 mmol, 4 equiv.) was added by syringe to a stirred solution of selenide 9 (164 mg, 0.392 mmol) in THF (10 mL) at room temperature. The mixture was cooled to 0 °C, and hydrogen peroxide (30% v/v; 532 µL, 15.7 mmol, 14 equiv.) was added dropwise. Stirring was continued at +7 °C for an additional 18 h. The reaction was then quenched with water and diluted with EtOAc. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with a saturated solution of NaHCO₃ and with brine, dried with MgSO₄, and filtered, and the solvents were evaporated in vacuo. The residue was purified by flash column chromatography (silica gel, n-hexane/EtOAc, 7:3) to give pure cyclopentenol 5a (54 mg, 60%). IR (neat): $\tilde{v} = 3504$, 3060, 2964, 2929, 2876, 1448, 1304, 1146, 1085, 742, 689 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 7.95 (m, 2 H), 7.75 (m, 1 H), 7.65 (m, 2 H), 6.00 (m, 1 H), 5.8 (m, 1 H), 4.77 (m, 1 H), 3.30 (m, 3 H), 3.20 (s 1 H), 2.70 (m, 1 H), 2.45 (m, 1 H), 1.50 (m, 2 H), 1.05 (m, 1 H), 0.85 (m, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 139.9 (s), 136.9 (d), 134.7 (d), 134.2 (d), 130.2 (d), 128.8 (d), 81.7 (d), 57.6 (t), 49.3 (d), 46.4 (d), 24.9 (t), 12.5 (q) ppm. MS (ESI): m/z (%) = 267 (100) [M + H]⁺. HRMS: calcd. for C₁₄H₁₈O₃S 266.0977; found 266.0981.

Cyclopentenol 5a (33.6 mg, 0.084 mmol) was dissolved in CH₂Cl₂/ ethyl vinyl ether (7:1; 1.5 mL), and PPTS (cat.) was added. The resulting mixture was stirred for 4 h, then excess solid NaHCO₃ was added, followed by a saturated solution of NaHCO₃ (5 mL). The layers were separated, and the aqueous phase was extracted with CH_2Cl_2 (3 × 15 mL). The combined organic phases were washed with brine, dried with Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel. Elution with n-hexane/EtOAc (8:2) gave acetal 5 (33.8 mg, 87%, 1:1 mixture of anomers) as a colourless oil. IR (neat): $\tilde{v} = 2973$, 1450, 1310, 1389, 1309, 1150, 1087, 999, 861, 692 cm⁻¹. ¹H NMR (300 MHz, CD₃COCD₃): δ = 7.90 (m, 2 H), 7.70 (m, 3 H), 6.00 (m, 1 H), 5.8 (m, 1 H), 4.75 (m, 1 H), 4.45 (m, 1 H), 3.30 (m, 3 H), 2.70 (m, 1 H), 2.50 (m, 1 H), 1.65 (m, 1 H), 1.27 (m, 3 H), 1.18 (m, 3 H), 1.06 (m, 1 H), 0.85 (t, J = 7.3 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CD₃COCD₃): δ = 141.3 (s), 140.3 (d), 139.3 (d), 134.4 (d), 133.7 (d), 130.2 (d), 128.7 (d), 101.0 (d), 98.7 (d), 81.8 (d), 77.4 (d), 61.2 (t), 60.0 (t), 49.4 (d), 41.5 (d), 21.2 (d), 20.6 (d), 18.9 (t), 15.8 (d), 12.5 (q) ppm. MS (ESI): m/z (%) = 339 (100) [M + H]⁺. HRMS: calcd. for C₁₈H₂₆O₄S 338.1552; found 338.1561.

Triisopropylsilyl Hept-6-ynoate (7): Imidazole (621 mg, 9.13 mmol, 1.3 equiv.) and then TIPSCI (1.6 mL, 7.37 mmol, 1.05 equiv.) were added to a solution of hept-6-ynoic acid (886 mg, 7.02 mmol) in dry CH₂Cl₂ (14 mL). The reaction mixture was stirred for 3 h at room temperature, then it was quenched with water (5 mL). The layers were separated, and the aqueous phase was extracted with CH_2Cl_2 (3 × 15 mL). The combined organic phases were washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel. Elution with *n*-hexane/MTBE (98:2) gave ester 7 (1.87 g, 99%) as a colourless oil. IR (neat): $\tilde{v} = 3313$, 2946, 2869, 1718, 1465, 1213 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 2.39 (t, J = 7.3 Hz, 2 H), 2.24 (td, J = 7.0, 2.6 Hz, 2 H), 1.96 (t, J = 2.7 Hz, 1 H), 1.77 (dd, J = 8.4, 7.3 Hz, 2 H), 1.62–1.57 (m, 2 H), 1.30 (td, J = 7.9, 6.1 Hz, 3 H), 1.09 (d, J = 7.3 Hz, 19 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 173.5 (s), 83.9 (s), 68.5 (d), 35.3 (t), 27.8 (t), 24.2 (t), 18.2 (t), 17.8 (q), 11.9 (d) ppm. MS (ESI): m/z (%) = 305 (100) [M + Na]⁺. HRMS: calcd. for C₁₆H₃₀O₂Si 282.2015; found 282.2020.

(S)-Methyl 10-(Benzyloxy)-9-hydroxydec-6-ynoate (12): *n*BuLi (0.49 mL, 1.24 mmol, 2 equiv.) was added dropwise to a solution of 7 (0.33 g, 1.23 mmol, 2 equiv.) in dry THF (6 mL) under Ar at -78 °C. After 1 h, BF₃·Et₂O (0.155 mL, 1.24 mmol, 2 equiv.) was added, and after 10 min, 8 (0.101 g, 0.62 mmol) in dry THF (2 mL) was added. The reaction was monitored by TLC (hexane/EtOAc, 8:2), and after 2 h at -78 °C was quenched with saturated aq. NH₄Cl (10 mL) and CH₂Cl₂ (15 mL). The aqueous layer was extracted with Na₂SO₄, filtered, and concentrated under vacuum. The residue was filtered through short pad of silica gel (hexane/EtOAc, 9:1) to give compound **11** (0.495 g, 90%) as a pale yellow oil, which was used immediately in the next step.

 $\rm H_2O~(2~mL)$ and $\rm K_2CO_3~(0.14~g,~1.01~mmol,~1.01~equiv.)$ were added to a magnetically stirred solution of **11** (0.45 g, 1.0 mmol) in THF (2 mL) at room temp. After 16 h of stirring at room temp., the reaction was quenched with saturated aq. NaHSO₄ (2 mL), $\rm H_2O~(2~mL)$, and $\rm CH_2Cl_2~(10~mL)$. The aqueous layer was extracted with $\rm CH_2Cl_2~(4 \times 6~mL)$, and the combined organic layers were washed with brine, dried with Na₂SO₄, filtered, and concentrated under vacuum.

The crude acid was dissolved in HPLC-grade MTBE (4 mL), and HPLC-grade MeOH (0.50 mL) was added. Solid-supported CAL-

B (80 mg) was added to the stirred solution, and the resulting suspension was gently stirred at 35 °C for 18 h. The enzyme was removed by filtration through a sintered glass funnel, and the solid was carefully washed with MeCN/MTBE (1:1, 4×2 mL). The filtrates were combined, and the solvents were evaporated under vacuum (CAUTION: without heating). The residue was purified by silica gel column chromatography (n-hexane/EtOAc, 7:3) to give pure ester 12 (213 mg, 70%). $[a]_D^{20} = +9.45$ (c = 0.85, CH₂Cl₂). IR (neat): $\tilde{v} = 3462, 2931, 1736, 1454, 1208, 1118, 739, 699 \text{ cm}^{-1}$. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.37-7.28$ (m, 5 H), 4.58 (s, 2 H), 3.93 (dd, J = 3.4, 3.2 Hz, 1 H), 3.67 (s, 3 H), 3.60 (dd, J = 9.5)4.0 Hz, 1 H), 3.50 (dd, J = 9.5, 6.6 Hz, 1 H), 2.61 (d, J = 3.8 Hz, 1 H), 2.42 (dt, J = 6.1, 2.5 Hz, 2 H), 2.33 (t, J = 7.4 Hz, 2 H), 2.18 (tt, J = 6.9, 2.4 Hz, 2 H), 1.72 (dt, J = 15.2, 7.5 Hz, 2 H), 1.51 (quint, J = 7.5 Hz, 2 H) ppm. ¹³C NMR (75 MHz, CDCl₃): $\delta =$ 173.8 (s), 137.9 (s), 128.3 (d), 127.6 (d), 81.9 (s), 76.0 (s), 73.3 (t), 72.9 (t), 69.1 (d), 51.4 (q), 33.4 (t), 28.2 (t), 24.0 (t), 23.8 (t), 18.3 (t) ppm. MS (ESI): m/z (%) = 305 (100) [M + H]⁺. HRMS: calcd. for C₁₈H₂₄O₄ 304.1675; found 304.1679.

Methyl (S)-10-(Benzyloxy)-9-[(tert-butyldimethylsilyl)oxy]dec-6ynoate (13): Imidazole (272 mg, 4 mmol, 2 equiv.) and TBSCl (361 mg, 2.4 mmol, 1.2 equiv.) were added to a solution of 12 (0.608 g, 2 mmol) in dry CH₂Cl₂ (6 mL) under Ar. The reaction was complete after 2 h, and it was quenched with H_2O (10 mL). The aqueous layer was extracted with CH_2Cl_2 (3 × 10 mL), and the combined organic layers were dried on MgSO₄, filtered, and concentrated under vacuum. The residue was purified by chromatography on silica gel column (n-hexane/EtOAc, 95:5) to give compound 13 (0.827 g, 99%) as a slightly yellow oil. $[a]_{D}^{20} =$ +2.96 (c = 2.2, CH₂Cl₂). IR (neat): $\tilde{v} = 2929$, 2857, 1741, 1436, 1362, 1255, 1123, 1006, 837, 778, 736 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.37-7.28$ (m, 5 H), 4.58 (s, 2 H), 3.93 (dd, J = 3.4, 3.2 Hz, 1 H), 3.67 (s, 3 H), 3.60 (dd, J = 9.5, 4.0 Hz, 1 H), 3.50 Hz(dd, J = 9.5, 6.6 Hz, 1 H), 2.61 (d, J = 3.8 Hz, 1 H), 2.42 (dt, J = 6.1, 2.5 Hz, 2 H), 2.33 (t, J = 7.4 Hz, 2 H), 2.18 (tt, J = 6.9, 2.4 Hz, 2 H), 1.72 (dt, J = 15.2, 7.5 Hz, 2 H), 1.51 (quint, J = 7.5 Hz, 2 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 173.9 (s), 1384 (s), 128.5 (d), 127.5 (d), 127.4 (d), 81.0 (s), 77.3 (s), 73.8 (t), 73.3 (t), 70.8 (d), 51.4 (q), 33.6 (t), 28.3 (t), 25.8 (q), 25.0 (t), 24.1 (t), 18.5 (t), 18.1 (s), -4.6 (q), 4.8 (q) ppm. MS (ESI): m/z (%) = 441 (100) $[M + Na]^+$. HRMS: calcd. for C₂₄H₃₈O₄Si 418.2539; found 418.2546.

Methyl (S)-9-[(tert-Butyldimethylsilyl)oxy]-10-hydroxydecanoate (14): Palladium on charcoal (10% Pd w/w; 80 mg) was added to a solution of 13 (0.766 mg, 1.88 mmol) in EtOAc/MeOH (9:1; 19 mL). The suspension was stirred at room temp. under a hydrogen atmosphere for 7 d. The suspension was filtered, and the solvent was removed from the filtrate under vacuum. The residue was purified by silica gel column chromatography (n-hexane/EtOAc, 95:5) to give compound 14 (0.537 g, 86%) as a colourless oil. $[a]_{D}^{20} = +7.19$ (c = 1.2, CH₂Cl₂). IR (neat): $\tilde{v} = 3468, 2930, 2857,$ 1742, 1464, 1362, 1255, 1116, 837, 776 cm⁻¹. ¹H NMR (300 MHz, $CDCl_3$): $\delta = 3.73-3.39$ (m, 6 H), 2.29 (t, J = 7.5 Hz, 2 H), 1.97 (t, J = 6.0 Hz, 1 H), 1.63–1.56 (m, 2 H), 1.48–1.44 (m, 2 H), 1.29– 1.23 (m, 8 H), 0.92 (s, 9 H), 0.07 (m, 6 H) ppm. ¹³C NMR $(75 \text{ MHz}, \text{CDCl}_3)$: $\delta = 174.2 \text{ (s)}, 72.8 \text{ (d)}, 66.2 \text{ (t)}, 51.4 \text{ (q)}, 34.0 \text{ (c)}$ (t), 33.9 (t), 29.5 (t), 29.1 (t), 29.0 (t), 25.8 (q), 25.2 (t), 24.8 (t), 18.0 (s), -4.5 (q), -4.6 (q) ppm. MS (ESI): m/z (%) = 333 (100) [M + H]⁺. HRMS: calcd. for $C_{17}H_{36}O_4Si$ 332.2383; found 332.2379.

Methyl (*S*)-9-[(*tert*-Butyldimethylsilyl)oxy]-10-oxodecanoate (6): Dess–Martin periodinane (DMP; 0.158 g, 0.37 mmol, 1.1 equiv.) was added to a solution of alcohol 14 (0.113 g, 0.34 mmol) in dry



CH₂Cl₂ (4 mL). The reaction was complete after 2 h, and was quenched with H₂O (8 mL), MTBE (9 mL), saturated aq. NaHCO₃ (5 mL), and saturated aq. Na₂S₂O₃ (5 mL). The aqueous layer was extracted with MTBE/*n*-hexane, 9:1. The combined organic layers were dried with Na₂SO₄, filtered, and concentrated under vacuum. The residue was filtered through silica gel (hexane/EtOAc, 9:1) to give compound **6** (85 mg, 75%) as a colourless oil, which was used in the next step without further purification. $[a]_{D}^{2O} = -22.12$ (*c* = 1.55, CH₂Cl₂). IR (neat): $\tilde{v} = 2930$, 2857, 1739, 1464, 1437, 1362, 1253, 1170, 1118, 1006, 838, 779, 666 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): $\delta = 9.4$ (d, *J* = 1.6 Hz, 1 H), 3.9 (m, 1 H), 3.6 (s, 3 H), 2.3 (t, *J* = 7.5 Hz, 2 H), 1.6 (m, 5 H), 1.3 (s, 9 H), 0.9 (m, 10 H), 0.1 (m, 6 H) ppm. MS (ESI): *m*/*z* (%) = 331 (100) [M + H]⁺.

Methyl (9S,E)-9-[(tert-Butyldimethylsilyl)oxy]-11-[(1S,4S,5R)-4-(1ethoxyethoxy)-5-ethylcyclopent-2-en-1-yl|undec-10-enoate (18): Sulfone 17 (22.5 mg, 0.067 mmol) was dissolved in dry THF (1.2 mL), and the solution was cooled to -78 °C. The solution was stirred for 10 min, and then *n*BuLi (2.5 M in hexane; 0.030 mL, 1.11 equiv.) was added dropwise. The mixture was stirred for 45 min at the same temperature, then the deep orange solution was slowly added by cannula to a solution of aldehyde 6 (25.3 mg, 0.077 mmol, 1.16 equiv.) in dry THF (0.4 mL). The solution was stirred at the same temperature for an additional 2 h, then a saturated solution of NH₄Cl (5 mL) was added at -78 °C, and the temperature was allowed to reach room temp. The two layers were separated, and the aqueous phase was extracted with CH_2Cl_2 (3 × 5 mL). The combined organic phases were washed with brine, dried with Na₂SO₄, and evaporated under reduced pressure. The crude product was filtered through a short pad of silica gel using n-hexane/EtOAc (8:2) as eluent. The crude hydroxysulfone was immediately used in the next step.

Crude hydroxysulfone (20 mg, 0.03 mmol) was dissolved in dry MeOH (2 mL) under an argon atmosphere. Na_2HPO_4 (190 mg) was added, and the slurry was cooled to -40 °C. The mixture was stirred vigorously for 10 min, then sodium amalgam (20% Na; 60 mg) was slowly added portionwise in such a way as to keep the temperature below -40 °C. At the end of the addition, the temperature was allowed to reach -20 °C, and stirring was continued for an additional 1.5 h. The mixture was warmed to room temp. and filtered through filter paper. Evaporation of volatiles in vacuo under 40 °C gave a residue, which was partitioned between CH₂Cl₂ (5 mL) and a saturated aqueous solution of NaHCO₃. The two phases were separated, and the aqueous layer was reextracted with CH_2Cl_2 (3 × 3 mL). The combined organic phases were washed with brine, dried with Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (10 g). Elution with n-hexane/EtOAc (94:6) gave compound **18** as a colourless oil (13.7 mg, 61%). IR (neat): $\tilde{v} = 2929$, 2360, 1736, 1466, 1273, 1123, 1074, 992, 836, 775, 668 cm⁻¹. ¹H NMR [300 MHz, (CD₃)₂CO]: δ = 6.05 (dddd, J = 14.2, 5.8, 2.3, 1.2 Hz, 1 H), 5.91 (ddd, J = 17.0, 5.8, 2.9 Hz, 1 H), 5.50–5.37 (m, 2 H), 4.76 (qd, J = 5.9, 5.3 Hz, 1 H), 4.47 (dd, J = 6.2, 2.3 Hz, 0.5 H), 4.33 (dd, J = 6.2, 2.4 Hz, 0.5 H), 4.15–4.08 (m, 1 H), 3.69–3.40 (m, 5 H), 3.17–3.08 (m, 1 H), 2.81–2.77 (m, 1 H), 2.30 (t, J = 7.4 Hz, 2 H), 2.10-1.97 (m, 2 H), 1.64-0.86 (m, 35 H), 0.12-0.09 (m, 6 H) ppm. ¹³C NMR [75 MHz, $(CD_3)_2CO$]: $\delta = 174.8$ (s), 148.0 (s), 141.3 (d), 141.1 (d), 140.3 (d), 136.2 (d), 136.1 (d), 134.1 (d), 133.6 (d), 133.3 (d), 133.0 (d), 132.8 (d), 132.6 (d), 101.8 (d), 99.4 (d), 83.1 (d), 79.4 (d), 74.9 (d), 74.9 (d), 61.7 (t), 60.5 (t), 52.2 (q), 52.1 (q), 51.9 (d), 50.3 (d), 50.3 (d), 40.1 (t), 35.1 (t), 27.1 (t), 26.9 (t), 26.7 (q), 26.4 (t), 22.0 (q), 21.4 (q), 20.7 (t), 20.6 (t), 19.5 (s), 16.5 (q), 13.8 (q), -3.2 (q), -3.8 (q) ppm. MS (ESI): m/z (%) = 534 (20) [M

FULL PAPER

+ Na – H_2O]⁺, 515 (80) [M + Na – H_2O]⁺. HRMS: calcd. for $C_{29}H_{54}O_5$ Si 510.3741; found 510.3746.

Methyl (S,E)-9-[(tert-Butyldimethylsilyl)oxy]-11-[(1R,5R)-5-ethyl-4oxocyclopent-2-en-1-yllundec-10-enoate (19): PPTS (cat.) was added to a stirred solution of acetal 18 (30 mg, 0.059 mmol) in EtOH/ CH₂Cl₂ (3:1; 2 mL), and the resulting mixture was stirred for 4 h. An excess of solid NaHCO₃ was added, and the resulting mixture was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel. Elution with nhexane/EtOAc (90:10) gave the desired alcohol (18.8 mg, 90%) as a colourless oil. $[a]_{D}^{20} = -77.0$ (c = 1.16, CH₂Cl₂). IR (neat): $\tilde{v} =$ 3502, 2931, 1713, 1472, 1358, 1360, 1254, 1077, 986, 840, 776 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 6.08–5.98 (m, 2 H), 5.43 (t, J = 5.8 Hz, 2 H), 4.52–4.49 (m, 1 H), 4.04 (q, J = 5.9 Hz, 1 H), 3.68 (s, 3 H), 3.21–3.10 (m, 1 H), 2.31 (t, J = 7.5 Hz, 2 H), 1.99 (quint, J = 7.0 Hz, 1 H), 1.65–1.22 (m, 18 H), 1.02 (t, J = 7.3 Hz, 3 H), 0.94-0.91 (m, 11 H), 0.05 (s, 3 H), 0.04 (s, 3 H) ppm. ¹³C NMR $(75 \text{ MHz}, \text{ CDCl}_3)$: $\delta = 174.3$ (s), 139.6 (d), 135.2 (d), 133.3 (d), 131.6 (d), 76.5 (d), 73.4 (d), 51.4 (d), 49.3 (q), 48.7 (d), 38.5 (t), 34.1 (t), 29.7 (t), 29.3 (t), 29.2 (t), 29.1 (t), 25.9 (q), 25.2 (t), 24.9 (t), 19.0 (t), 18.2 (t), 12.7 (q), -4.3 (q), -4.8 (q) ppm. MS (ESI): m/z $(\%) = 421 (100) [M - H_2O]^+, 515 (80) [M + Na - H_2O]^+.$ HRMS: calcd. for C₂₅H₄₆O₄Si 438.3165; found 438.3151.

DMP (23.7 mg, 0.056 mmol, 1.2 equiv.) was added to a stirred solution of the alcohol prepared as described above (20.4 mg, 0.047 mmol) in dry CH₂Cl₂ (1 mL). After 30 min, Et₂O (6 mL) was added, and the resulting mixture was filtered through a short pad of silica gel, which was thoroughly washed with n-hexane/Et₂O (9:1; 70 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel. Elution with n-hexane/EtOAc (9:1) gave compound **19** (19.3 mg, 95%) as a colourless oil. $[a]_{D}^{20} = -129.5$ (c = 0.42, EtOAc). IR (neat): $\tilde{v} = 3734$, 2929, 2856, 2360, 1741, 1712, 1587, 1462, 1251, 1778, 1250, 1073, 836, 776, 668 cm⁻¹. ¹H NMR (300 MHz, CD₃CN): δ = 7.55 (dd, J = 5.7, 2.9 Hz, 1 H), 6.13 (dd, *J* = 5.7, 1.7 Hz, 1 H), 5.58 (dd, *J* = 15.4, 6.0 Hz, 1 H), 5.40 (dd, *J* = 15.5, 8.8 Hz, 1 H), 4.17 (q, J = 6.1 Hz, 1 H), 3.74–3.73 (m, 1 H), 3.62 (s, 3 H), 2.34–2.27 (m), 1.97 (dtd, J = 4.9, 2.5, 0.5 Hz, 1 H), 1.61-1.25 (m, 14 H), 0.99 (t, J = 7.4 Hz, 3 H), 0.92-0.86 (m, 11 H), 0.07–0.00 (m, 6 H) ppm. ¹³C NMR (75 MHz, CD₃CN): δ = 211.3 (s), 174.6 (s), 166.2 (d), 138.2 (d), 132.8 (d), 127.7 (d), 73.5 (d), 51.8 (d), 51.6 (q), 48.0 (d), 38.8 (t), 34.3 (t), 29.8 (t), 29.7 (t), 29.5 (t), 26.0 (q), 25.6 (t), 25.5 (t), 20.2 (t), 18.6 (s), 12.8 (q), -4.4 (q), -4.8 (q) ppm. MS (ESI): m/z (%) = 459 (100) [M + Na]⁺. HRMS: calcd. for C₂₅H₄₄O₄Si 436.3009; found 436.3013.

(S,E)-11-[(1R,5R)-5-ethyl-4-oxocyclopent-2-en-1-yl]-9-hydroxyundec-10-enoic Acid (9-J₁-PhytoP; 1): Aqueous HF (48%; 0.063 mL) was added to a stirred solution of silyl ether 19 (17.1 mg, 0.0392 mmol) in HPLC-grade CH₃CN (4 mL) in a PE (polyethylene) test tube. After 4 h, a phosphate buffer (pH 6.8, 5 mL) was added. The layers were separated, and the aqueous phase was extracted with EtOAc (4×5 mL). The combined organic phases were washed with brine, dried with MgSO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel. Elution with n-hexane/EtOAc (6:4) gave pure 9-J₁-PhytoP-Me-Ester (13.9 mg, 93%) as a pale yellow oil. $[a]_{D}^{20} = -170.4$ (c = 0.55, EtOAc). IR (neat): $\tilde{v} = 3445$, 2929, 1738, 1713, 1699, 1694, 1559, 1456 cm⁻¹. ¹H NMR (300 MHz, CD₃CN): δ = 7.57 (dd, J = 5.7, 2.9 Hz, 1 H), 6.14 (dd, J = 5.7, 1.8 Hz, 1 H), 5.59 (ddd, J = 15.4, 6.2, 0.6 Hz, 1 H), 5.42 (ddd, J = 15.4, 8.7, 1.0 Hz, 1 H), 4.00 (quint, J = 5.6 Hz, 1 H), 3.74–3.73 (m, 1 H), 3.61 (s, 3 H), 2.75 (d, J = 4.7 Hz, 1 H), 2.30 (t, J = 7.5 Hz,

3 H), 1.96 (dt, J = 4.9, 2.5 Hz, 1 H), 1.68–1.25 (m, 14 H), 1.00 (t, J = 7.4 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CD₃CN): $\delta = 211.4$ (s), 174.6 (s), 166.2 (d), 138.4 (d), 132.9 (d), 127.7 (d), 72.2 (d), 51.7 (d), 51.6 (q), 48.0 (d), 38.0 (t), 34.3 (t), 29.8 (t), 29.7 (t), 29.5 (t), 25.9 (t), 25.4 (t), 20.3 (t), 12.6 (q) ppm. MS (ESI): m/z (%) = 355 (100) [M + Na]⁺. HRMS: calcd. for C₁₉H₃₀O₄ 332.2144; found 332.2133.

The methyl ester prepared as described above (11.1 mg, 0.034 mmol) was dissolved in HPLC-grade MTBE (0.4 mL), and HPLC-grade H₂O (0.043 mL, 2.4 mmol, 70 equiv.) was added. Solid-supported CAL-B (2 mg) was added to the resulting stirred solution, and the suspension was gently stirred at room temperature for 18 h. The enzyme was removed by filtration through a sintered glass funnel, and the solid was carefully washed with MeCN/ MTBE (1:1; 4×2 mL). The filtrates were combined, and the solvents were evaporated under vacuum (CAUTION: without heating). The residue was purified by silica gel column chromatography (hexane/EtOAc, 1:1, with 0.5% AcOH) to give pure acid 1 (6.7 mg, 90%) as a pale yellow oil. $[a]_{D}^{20} = -129.1$ (c = 0.11, EtOAc). IR (neat): $\tilde{v} = 3313, 2928, 1705, 1581, 1240, 968 \text{ cm}^{-1}$. ¹H NMR (300 MHz, CD₃CN): δ = 7.57 (dd, J = 5.7, 2.8 Hz, 1 H), 6.15 (dd, J = 5.7, 1.8 Hz, 1 H), 5.56 (ddd, J = 15.4, 6.0, 0.6 Hz, 1 H), 5.39 (ddd, J = 15.4, 8.8, 1.0 Hz, 1 H), 4.00 (quint, J = 5.4 Hz, 1 H),3.8-3.7 (m, 2 H), 2.48-1.94 (m, 9 H), 1.75-1.15 (m, 10 H), 1.04 (t, J = 7.3 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CD₃CN): $\delta = 211.4$ (s), 174.9 (s), 166.2 (d), 138.4 (d), 132.9 (d), 127.8 (d), 72.2 (d), 51.6 (q), 48.0 (d), 38.0 (t), 34.0 (t), 29.9 (t), 29.7 (t), 29.5 (t), 25.8 (t), 25.4 (t), 20.3 (t), 12.6 (q) ppm. MS (ESI): m/z (%) = 309 (100) [M + H]⁺. HRMS: calcd. for $C_{18}H_{28}O_4$ 308.1988; found 308.1992.

Methyl (*S*,*E*)-9-[(*tert*-Butyldimethylsilyl)oxy]-11-[(1*S*,2*S*)-2-ethyl-5oxocyclopent-3-en-1-yl]undec-10-enoate (20)

Julia-Lythgoe Olefination: Following the same procedure used for compound 18, sulfone 5 (39.4 mg, 0.117 mmol) underwent the Julia–Lythgoe olefination reaction to give compound S1 (23.6 mg, 60%) as a colourless oil. IR (neat): $\tilde{v} = 2929, 2360, 1736, 1461,$ 1273, 1123, 1074, 992, 836, 775, 668 cm⁻¹. ¹H NMR (300 MHz, CD₃CN): δ = 5.98 (m, 1 H), 5.77 (m, 1 H), 5.65–5.45 (m, 2 H), 4.76 (qd, J = 5.9, 5.3 Hz, 1 H), 4.47 (dd, J = 6.2, 2.3 Hz, 1 H), 4.33(dd, J = 6.2, 2.4 Hz, 1 H), 4.15–4.08 (m, 1 H), 3.69–3.40 (m, 4 H), 3.17-3.08 (m, 1 H), 2.78-2.66 (m, 1 H), 2.30 (t, J = 7.4 Hz, 2 H), 2.10-1.97 (m, 2 H), 1.64-0.86 (m, 34 H), 0.12-0.09 (m, 6 H) ppm. ¹³C NMR [75 MHz, (CD₃)₂CO]: δ = 173.8 (s), 138.0 (s), 137.6 (d), 135.6 (d), 135.6 (d), 131.8 (d), 130.9 (d), 129.2 (d), 129.0 (d), 133.3 (d), 133.0 (d), 132.8 (d), 132.6 (d), 101.8 (d), 99.4 (d), 83.1 (d), 79.4 (d), 74.9 (d), 74.9 (d), 60.5 (t), 60.1 (t), 52.2 (q), 51.8 (q), 50.8 (d), 49.2 (d), 49.1 (d), 38.2 (t), 33.5 (t), 29.1 (t), 28.9 (t), 28.9 (q), 28.7 (t), 22.0 (q), 21.4 (q), 20.7 (t), 20.6 (t), 19.5 (s), 16.5 (q), 13.8 (q), -5.0 (q), -5.4 (q) ppm. MS (ESI): m/z (%) = 534 (20) [M + Na]⁺. HRMS: calcd. for C₂₉H₅₄O₅Si 510.3741; found 510.3749.

EE Deprotection: Following the same procedure used for compound **18**, EE-protected cyclopentenol **S1** (39.4 mg, 0.077 mmol) gave free cyclopentenol **S2** (24.6 mg, 91%) as a colourless oil. IR (neat): $\tilde{v} = 3502$, 2931, 1713, 1472, 1358, 1360, 1254, 1077, 986, 840, 776 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): $\delta = 5.98-5.96$ (m, 1 H), 5.78-5.76 (m, 1 H), 5.65-5.45 (m, 2 H), 4.52-4.49 (m, 1 H), 4.04 (q, J = 5.9 Hz, 1 H), 3.68 (s, 3 H), 2.77-2.51 (m, 3 H), 2.31 (t, J = 7.5 Hz, 2 H), 1.99 (m, 1 H), 1.65-1.22 (m, 14 H), 1.00-0.65 (m, 10 H), 0.05 (s, 3 H), 0.04 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): $\delta = 174.3$ (s), 139.6 (d), 135.2 (d), 133.3 (d), 131.6 (d), 76.5 (d), 73.4 (d), 51.4 (d), 49.3 (q), 48.7 (d), 38.5 (t), 34.1 (t), 29.7 (t), 29.3 (t), 29.2 (t), 29.1 (t), 25.9 (q), 25.2 (t), 24.9 (t), 19.0 (t), 18.2 (t), 12.7 (q), -4.3 (q), -4.8 (q) ppm. MS (ESI): *m/z* (%) = 421 (100)



 $[M + H]^+$. HRMS: calcd. for $C_{25}H_{46}O_4Si$ 438.3165; found 438.3153.

DMP Oxidation: DMP (28.4 mg, 0.067 mmol, 1.2 equiv.) was added to a stirred solution of cyclopentenol ester S2 (24.5 mg, 0.056 mmol) in dry CH₂Cl₂ (1.5 mL). After 30 min, Et₂O (6 mL) was added, and the resulting mixture was filtered through a short pad of silica gel, which was then thoroughly washed with n-hexane/ Et₂O (9:1, 70 mL). The resulting mixture was concentrated under reduced pressure WITHOUT HEATING! The residue was purified by flash chromatography on silica gel. Elution with n-hexane/ EtOAc (9:1) gave compound 20 (7.2 mg, 31%) as a pale yellow oil. $[a]_{\rm D}^{20}$ = 23.6 (c = 0.275, EtOAc). IR (neat): \tilde{v} = 3734, 2929, 2856, 2360, 1741, 1712, 1587, 1462, 1251, 1778, 1250, 1073, 836, 776, 668 cm⁻¹. ¹H NMR (300 MHz, CD₃CN): δ = 7.55 (dd, J = 5.7, 2.9 Hz, 1 H), 6.13 (dd, J = 5.7, 1.7 Hz, 1 H), 5.70–5.30 (m, 2 H), 4.17 (m, 1 H), 3.62 (s, 3 H), 3.2–2.9 (m, 2 H), 2.5–1.9 (m, 10 H), 1.75-1.3 (m, 9 H), 0.95 (t, J = 7.4 Hz, 3 H), 0.92-0.86 (m, 6 H), 0.07–0.00 (m, 6 H) ppm. ¹³C NMR (75 MHz, CD₃CN): δ = 211.3 (s), 174.6 (s), 166.2 (d), 138.2 (d), 132.8 (d), 127.7 (d), 73.5 (d), 51.8 (d), 51.6 (q), 48.0 (d), 38.8 (t), 34.3 (t), 29.8 (t), 29.7 (t), 29.5 (t), 26.0 (q), 25.6 (t), 25.5 (t), 20.2 (t), 18.6 (s), 12.8 (q), -4.4 (q), -4.8 (q) ppm. MS (ESI): m/z (%) = 437 (100) [M + H]⁺. HRMS: calcd. for C₂₅H₄₄O₄Si 436.3009; found 436.3015.

Methyl (S,E)-11-[(1S,2S)-2-ethyl-5-oxocyclopent-3-en-1-yl]-9-hydroxyundec-10-enoate (9-A₁-PhytoP-Me-Ester; 21): NH₄F (7 M aq.; 0.057 mL, 10 equiv.) was added to a stirred solution of silvl ether 20 (6.9 mg, 0.0196 mmol) in HPLC-grade CH₃OH (2 mL) in a PE test tube. After 4 h, a phosphate buffer (pH 6.8, 3 mL) was added. The layers were separated, and the aqueous phase was extracted with EtOAc (4×3 mL). The combined organic phases were washed with brine, dried with MgSO₄, filtered, and concentrated under reduced pressure WITHOUT HEATING! The residue was purified by flash chromatography on silica gel. Elution with n-hexane/ EtOAc (6:4) gave pure $9-A_1$ -PhytoP-Me-Ester 21 (1.4 mg, 31%) as a pale yellow oil. $[a]_{D}^{20} = 67.5$ (c = 0.12, MeCN). IR (neat): $\tilde{v} =$ 3448, 2930, 1739, 1715, 1700, 1693, 1555, 1453 cm⁻¹. ¹H NMR (400 MHz, CD₃CN): δ = 7.57 (dd, J = 5.7, 2.3 Hz, 1 H), 6.10 (dd, J = 5.7, 2.0 Hz, 1 H), 5.63 (dd, J = 15.5, 6.2 Hz, 1 H), 5.52 (dd, J= 15.6, 7.7 Hz, 1 H), 3.98 (quint, J = 5.6 Hz, 1 H), 3.61 (s, 3 H), 2.75-2.55 (m, 3 H), 2.30 (t, J = 7.5 Hz, 2 H), 1.78-1.25 (m, 14 H), 1.00 (t, J = 7.4 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CD₃CN): $\delta =$ 209.74 (s), 174.92 (s), 168.2 (d), 138.0 (d), 132.9 (d), 127.7 (d), 72.6 (d), 55.7 (d), 51.9 (q), 50.7 (d), 38.3 (t), 34.6 (t), 30.0 (t), 29.8 (t), 27.5 (t), 26.2 (t), 25.7 (t), 14.5 (t), 12.2 (q) ppm. MS (ESI): m/z (%) = 355 (100) $[M + Na]^+$. HRMS: calcd. for $C_{19}H_{30}O_4$ 332.2144; found 332.2135.

Supporting Information (see footnote on the first page of this article): Synthetic sequence for the conversion of **5** into **20**. Copies of the 1 H, 13 C, and DEPT NMR spectra are provided.

Acknowledgments

This work was supported by Regione Lombardia (Direzione Generale Sanità and Iniziativa Lombardia Eccellente), Fondazione di Piacenza e Vigevano, and Ministero dell'Università e della Ricerca (MIUR) (PRIN fund).

- a) S. Parchmann, M. J. Mueller, J. Biol. Chem. 1998, 273, 32650–32655; b) M.-J. Mueller, Curr. Opin. Plant Biol. 2004, 7, 441–448; c) for a recent review, see: U. Jahn, J.-M. Galano, T. Durand, Angew. Chem. 2008, 120, 5978–6041; Angew. Chem. Int. Ed. 2008, 47, 5894–5955.
- [2] For the recent nomenclature system, see: a) M. J. Muller, *Prostaglandins Leukotrienes Essent. Fatty Acids* 2010, 82, 71–81; b) U. Jahn, J.-M. Galano, T. Durand, *Prostaglandins Leukotrienes Essent. Fatty Acids* 2010, 82, 83–86. For the older nomenclature system, see: c) M. J. Muller, *J. Chem. Biol.* 1998, 5, 323–333.
- [3] I. Thoma, C. Loeffler, A. K. Sinha, M. Gupta, M. Krischke, B. Steffan, T. Roitsch, M. J. Mueller, *Plant J.* 2003, 34, 363– 375.
- [4] M. Krischke, C. Loeffler, M. J. Mueller, *Phytochemistry* 2003, 62, 351–358.
- [5] S. Mueller, B. Hilbert, K. Dueckershoff, T. Roitsch, M. Krischke, M. J. Mueller, S. Berger, *Plant Cell* 2008, 20, 768– 785.
- [6] K. Karg, V. M. Dirsch, A. M. Vollmar, J.-L. Cracowski, F. Laporte, M. J. Mueller, *Free Radical Res.* 2007, 41, 25–37.
- [7] a) G. Zanoni, F. Agnelli, A. Meriggi, G. Vidari, *Tetrahedron: Asymmetry* 2001, *12*, 1779–1784; b) G. Zanoni, A. Porta, A. Meriggi, M. Franzini, G. Vidari, *J. Org. Chem.* 2002, 67, 6064– 6069.
- [8] G. Zanoni, F. Castronovo, E. Perani, G. Vidari, J. Org. Chem. 2003, 68, 6803–6805.
- [9] G. W. J. Fleet, P. J. C. Harding, M. J. Whitcombe, *Tetrahedron Lett.* 1980, 21, 4031–4034.
- [10] a) M. Yamaguchi, I. Hirao, *Tetrahedron Lett.* 1983, 24, 391–394; b) H. Seike, I. Ghosh, Y. Kishi, *Org. Lett.* 2006, 8, 3865–3868.
- [11] D. B. Dess, J. C. Martin, J. Am. Chem. Soc. 1991, 113, 7277-7287.
- [12] H. A. Earl, C. J. M. Stirling, J. Chem. Soc. Perkin Trans. 2 1987, 1273–1280.
- [13] G. Zanoni, A. Porta, G. Vidari, J. Org. Chem. 2002, 67, 4346– 4351.
- [14] G. Zanoni, M. Valli, L. Bendjeddou, A. Porta, P. Bruno, G. Vidari, J. Org. Chem. 2010, 75, 8311–8314.
- [15] It should be emphasized that in all the phytoprostane syntheses reported to date, instead of the naturally occurring free acids, the corresponding methyl esters, are prepared. See ref.^[1c], and references cited therein. See also: A. Vázquez-Romero, L. Cárdenas, E. Blasi, X. Verdaguer, A. Riera, *Org. Lett.* **2009**, *11*, 3104–3107 and W. Perlikowska, M. Mikolajczyk, *Tetrahedron: Asymmetry* **2011**, 22, 1767–1771.

Received: November 12, 2013 Published Online: January 29, 2014